Abdominal Infection, Bacteremia, Enterobacteriaceae Infections, Ventilator Associated Pneumonia
Conditions
Brief summary
Worldwide emergence of extended-spectrum β-lactamase-producing Enterobacteriaceae (ESBL-E) had become a major problem in ICU, with at least 10% of incidence at the admission in Europe. A systematic rectal swab is used in 70% of French ICU to detect intestinal ESBL-E carriage The relationship between intestinal carriage and ICU-acquired infection is not perfectly known. The investigators conducted a five years study monocentric retrospective observational cohort in patients with presence of extended-spectrum β-lactamase-producing Enterobacteriaceae in systematic rectal swabs to investigate which type of infections and which bacteria are involved. The investigators also collect data about antibiotherapy used to treat these infections.
Detailed description
Intestinal carriage of extended-spectrum β-lactamase-producing Enterobacteriaceae (ESBL-E) had become a major problem in general population, morover in intensive care units. Systematic rectal swab for screening is done in 70% of French ICU in routine. Some studies had show a good negative predictive value of this test for ICU-acquired infection (for example ventilator-associated pneumoniae), but a poor predictive positive value. The precise relationship between intestinal carriage and ICU-acquired infection is not perfectly known. Probabilist antibiotherapy with carbapenem for ESBL-E suspected infection are currently recommanded by national and european Guidelines, particulary in case of shock or immunodepression. A ESBL-E systematic screening-guided strategy for probabilist antibiotherapy could be interesting, and could lead to a carbapenem or a carbapenem-sparing focused antibiotherapy. The investigators conducted a monocentric retrospective observational cohort study in patients with presence of extended-spectrum β-lactamase-producing Enterobacteriaceae in systematic rectal swabs to investigate the number of ESBL-E related infections, the site of these infections and which species of bacteriae are involved. They also investigate which was the antibiotherapy administered, and investigate what factors lead clinicians to treat the infection with carbapenem antibiotherapy.
Interventions
observational
Sponsors
Study design
Eligibility
Inclusion criteria
* admitted in Brest ICU (medical or surgical) * positive rectal swab for ESBL-Enterobacteriae screening at the admission or during the ICU stay * written consent
Exclusion criteria
* refusing to participate
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| proportion of ESBL-E related infection in ICU-aquired infection | 28 days | proportion of ESBL-E related infection in ICU-aquired infection |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| use of carbapenem antibiotherapy | 28 days | use of carbapenem antibiotherapy |
| length of ICU-stay | 28 days | length of ICU-stay |
| length of hospital-stay | 28 days | length of hospital-stay |
| mortality rate in ICU | 28 days | death in ICU |
| mortality in hospital | 28 days | death in hospital |
Countries
France